Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.63 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518635 | 0.86 | ABL1 (0.61) | ABL1 | |
| SCHEMBL28525034 | 0.85 | ABL1 (0.64) | ABL1 | |
| SCHEMBL28532757 | 0.83 | ABL1 (0.62) | ABL1 | |
| SCHEMBL22938707 | 0.83 | ABL1 (0.64) | ABL1BCRKCNH2CRBN | |
| SCHEMBL30046879 | 0.83 | ABL1 (0.64) | ABL1BCRKCNH2CRBN | |
| SCHEMBL22938735 | 0.82 | ABL1 (0.61) | ABL1 | |
| SCHEMBL28525030 | 0.82 | ABL1 (0.54) | ABL1 | |
| SCHEMBL28534208 | 0.82 | ABL1 (0.61) | ABL1 | |
| SCHEMBL30046930 | 0.82 | ABL1 (0.60) | ABL1 | |
| SCHEMBL30046510 | 0.82 | ABL1 (0.60) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | claimed |
| CN-112300129-B | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-09-14 | — | — | CN | claimed |
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | disclosed |
| CN-112300129-B | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-112300129-A | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ABL1, ABL2, BCR | ABL1 1/4885BCR 3/4885KCNH2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.